English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In recent years, long non-coding RNAs have emerged as a novel class of regulators of cancer biological processes. While they are dysregulated in many cancer types, little is known about their expression and functional profiles. This study has been focused on the determination of the role of a specific lncRNA in papillary thyroid cancer. Quantitative reverse transcription PCR was performed to detect the expression levels of 84 lncRNAs in 61 papillary thyroid carcinoma tissues and their adjacent non-tumor tissues. The highest fold-change was obtained for lung cancer associated transcript 1  LUCAT1 , and thus, this study determines the expression and biological implication of lncRNA  LUCAT1  through different  in vitro  and  ex vivo  approaches in this tumor.  LUCAT1  was specifically located at the cell nucleus in tumoral regions of patient tissues. Furthermore,  LUCAT1  knockdown significantly reduced both cell proliferation and invasion  ex vivo  and induced cell-cycle arrest and apoptosis. These facts were corroborated by an enhanced expression of  P21 ,  P57 ,  P53  and  BAX , and a reduced expression of  EZH2  and  HDAC1 . In addition, a significant decrease was observed on  DNMT1  and  NRF2  genes, helping to clarify the role of  LUCAT1  on PTC. Our study reveals the involvement of  LUCAT1  in PTC development, through acting in cell-cycle regulation, proliferation, epigenetic modifications through LUCAT1/ CDK1/ EZH2/ P57/ P21/ HDAC1/ DNMT1/ P53/ BAX axis and apoptosis, via extrinsic pathway activating caspases. These findings indicate that  LUCAT1  is maybe a potential therapeutic target and molecular biomarker for PTC.

LncRNA LUCAT1 as a novel prognostic biomarker for patients with papillary thyroid cancer